Pfizer and Mylan say they have agreed to settle their patent infringement lawsuit against the French drugmaker Sanofi over pre-filled injections designed to treat severe allergic reactions.
Terms of the settlement were not disclosed in Thursday's announcement.
Pfizer Inc. makes the EpiPen injection device and Mylan Inc. markets it in the U.S. The companies claimed Sanofi and its partner Intelliject had infringed on their patents with their e-cue injection device.
In the settlement, Sanofi and its partner agreed they won't start selling the e-cue product before Nov. 15.
The settlement will be reviewed by the U.S. Department of Justice and the Federal Trade Commission.
Mylan shares rose 33 cents to $23.49 in afternoon trading, while Pfizer stock added 25 cents to $21.36. Sanofi's U.S. shares gained 20 cents to $37.14.